文献速递消化系统肿瘤

分子筛选的转移性结直肠癌中西妥昔单抗再挑战:随机CAVE-2 GOIM试验

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.
PubMed 文献 · Ann Oncol · 2025-12-22

CAVE-2 GOIM是一项随机II期试验,在RAS/BRAF野生型mCRC患者中比较西妥昔单抗联合avelumab与西妥昔单抗再挑战,按基线血浆ctDNA CGP筛选。联合avelumab未显著改善PFS或OS。探索性分析显示,无EGFR通路相关基因变异(「阴性超选择」)患者从再挑战中获益更显著。

要点

  • 联合avelumab未提高西妥昔单抗再挑战的疗效。
  • ctDNA CGP「阴性超选择」患者PFS和OS显著更优。
  • 液体活检CGP可识别抗EGFR再挑战获益人群。

核心结论

  • 在RAS/BRAF野生型mCRC中,西妥昔单抗联合avelumab再挑战未较西妥昔单抗单药改善PFS或OS。
  • ctDNA CGP定义的「阴性超选择」患者从抗EGFR再挑战中获益更显著。

研究设计与样本

  • 随机II期CAVE-2 GOIM试验,纳入RAS/BRAF野生型mCRC患者,按基线血浆ctDNA CGP(FoundationOne Liquid CDx)筛选。
  • 2022年8月至2024年12月,328例筛查患者中156例随机2:1分配至西妥昔单抗联合avelumab组(A组,104例)或西妥昔单抗组(B组,52例)。
  • 主要终点为总生存期(OS)。

主要发现

  • A组中位PFS为5.3个月(95%CI 4.3-6),B组为4.3个月(95%CI 3.5-5.5),HR 0.78(95%CI 0.55-1.10,P=0.158)。
  • A组中位OS为14.8个月(95%CI 12.1-18.3),B组为12.9个月(95%CI 11-不可评估),HR 1.00(95%CI 0.65-1.52,P=0.983)。
  • 全研究人群中,124/156例患者肿瘤无KRAS、NRAS、BRAF、EGFR胞外域、PIK3CA外显子20、MAP2K1、AKT1、MET、PTEN和ERBB2基因变异(「阴性超选择」)。
  • 「阴性超选择」患者较至少携带一种致病性变异(「阳性超选择」)患者的中位PFS显著改善:5.35个月(95%CI 4.4-5.9)vs 3.65个月(95%CI 2.8-4.8),HR 0.62(95%CI 0.42-0.92,P=0.017)。
  • 「阴性超选择」患者的中位OS也显著改善:15.0个月(95%CI 12.6-19.9)vs 11.1个月(95%CI 8.6-15.6),HR 0.61(95%CI 0.39-0.97,P=0.037)。

关键数值与推荐

  • 「阴性超选择」定义为肿瘤无KRAS、NRAS、BRAF、EGFR胞外域、PIK3CA外显子20、MAP2K1、AKT1、MET、PTEN和ERBB2基因变异。
  • 「阴性超选择」患者中位PFS为5.35个月(95%CI 4.4-5.9),「阳性超选择」患者为3.65个月(95%CI 2.8-4.8)。
  • 「阴性超选择」患者中位OS为15.0个月(95%CI 12.6-19.9),「阳性超选择」患者为11.1个月(95%CI 8.6-15.6)。

临床怎么用

  • 对于RAS/BRAF野生型mCRC患者,不推荐在再挑战时常规联合avelumab。
  • 可基于基线血浆ctDNA CGP筛选「阴性超选择」患者,以识别抗EGFR再挑战的潜在获益人群。
  • 液体活检CGP可整合至mCRC全程管理中以指导治疗决策。

局限性

  • 本研究为II期试验,样本量有限。
  • 「阴性超选择」分析为预先计划的探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-epidermal growth factor receptor (EGFR) drug rechallenge could be of therapeutic value in a subgroup of refractory metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: The randomized phase II CAVE-2 GOIM trial compared two rechallenge regimens in RAS/BRAF wild-type mCRC (cetuximab monotherapy or in combination with avelumab). Patients were selected according to baseline plasma circulating tumor DNA (ctDNA) comprehensive genomic profiling (CGP) by FoundationOne Liquid CDx. Primary endpoint was overall survival (OS). RESULTS: From August 2022 to December 2024, 156 out of 328 screened patients were randomly assigned in a 2 : 1 ratio to cetuximab plus avelumab (arm A, 104 patients) or cetuximab (arm B, 52 patients). Median progression-free survival (mPFS) was 5.3 months [95% confidence interval (CI) 4.3-6 months] in arm A versus 4.3 months (95% CI 3.5-5.5 months) in arm B [hazard ratio (HR) 0.78, 95% CI 0.55-1.10, P = 0.158]. Median OS (mOS) was 14.8 months (95% CI 12.1-18.3 months) in arm A versus 12.9 months (95% CI 11 months-not evaluable) in arm B (HR 1.00, 95% CI 0.65-1.52, P = 0.983). A pre-planned exploratory analysis evaluated the impact of genomic pathogenic variants on therapeutic efficacy in the EGFR pathway. In the whole study population, 124/156 patients had tumors without any genomic alteration in KRAS, NRAS, BRAF, EGFR extracellular domain, PIK3CA exon 20, MAP2K1, AKT1, MET, PTEN, and ERBB2 ('negative hyperselection'). These patients had significantly improved mPFS [5.35 months (95% CI 4.4-5.9 months) versus 3.65 months (95% CI 2.8-4.8 months); HR 0.62, 95% CI 0.42-0.92, P = 0.017] and mOS [15.0 months (95% CI 12.6-19.9 months) versus 11.1 months (95% CI 8.6-15.6 months); HR 0.61, 95% CI 0.39-0.97, P = 0.037] compared with patients having at least one pathogenic variant ('positive hyperselection'). Similarly, improved objective response rate, mPFS, and OS were observed for each treatment arm in patients with 'negative hyperselection'. CONCLUSION: Addition of avelumab does not increase efficacy of cetuximab rechallenge. Liquid biopsy CGP identifies patients who benefit from anti-EGFR rechallenge supporting its implementation in the continuum of care of mCRC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ciardiello D, Martini G, Boscolo Bielo L, et al. Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial. Ann Oncol. 2025. PMID: 41443411. doi:10.1016/j.annonc.2025.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。